Mark Schneyer Sells 5,849 Shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock

Key Points

• ACADIA executive Mark Schneyer sold 5,849 shares for approximately $169,621 at an average price of $29.00 under a pre-arranged Rule 10b5-1 plan, reducing his stake by 7.94%.
• ACADIA reported a quarterly earnings beat, with EPS of $0.18 versus the $0.07 consensus estimate and revenue of $308 million, up 16.4% year over year.
• The stock rose 2.7% to $29.21, while analysts maintained a broadly positive outlook: 14 rated it Buy and three Hold, producing a “Moderate Buy” consensus and an average price target of $33.44.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Get Free Report) EVP Mark Schneyer sold 5,849 shares of the company's stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $29.00, for a total transaction of $169,621.00. Following the completion of the transaction, the executive vice president owned 67,828 shares in the company, valued at approximately $1,967,012. This trade represents a 7.94% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

ACADIA Pharmaceuticals Trading Up 2.7%

ACAD stock traded up $0.76 during mid-day trading on Friday, hitting $29.21. 1,782,652 shares of the company were exchanged, compared to its average volume of 1,684,264. ACADIA Pharmaceuticals Inc. has a 1-year low of $19.69 and a 1-year high of $29.48. The stock has a market capitalization of $5.00 billion, a PE ratio of 13.16, a price-to-earnings-growth ratio of 19.47 and a beta of 0.81. The business has a 50 day simple moving average of $24.24 and a 200-day simple moving average of $23.23.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last announced its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.18 earnings per share for the quarter, topping analysts' consensus estimates of $0.07 by $0.11. The company had revenue of $308.00 million for the quarter, compared to analyst estimates of $296.55 million. ACADIA Pharmaceuticals had a return on equity of 9.03% and a net margin of 33.42%.The firm's quarterly revenue was up 16.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.16 earnings per share. Equities research analysts expect that ACADIA Pharmaceuticals Inc. will post 0.4 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Stifel Nicolaus lifted their target price on ACADIA Pharmaceuticals from $24.00 to $25.00 and gave the stock a "hold" rating in a report on Tuesday, July 21st. Citizens Jmp upped their price target on shares of ACADIA Pharmaceuticals from $35.00 to $36.00 and gave the company a "market outperform" rating in a research note on Wednesday. Canaccord Genuity Group raised their price target on shares of ACADIA Pharmaceuticals from $32.00 to $36.00 and gave the stock a "buy" rating in a research report on Monday, June 29th. Deutsche Bank Aktiengesellschaft reiterated a "buy" rating and issued a $37.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Monday, June 29th. Finally, Bank of America reissued a "buy" rating and issued a $14.50 price objective on shares of ACADIA Pharmaceuticals in a report on Wednesday, July 29th. Fourteen analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $33.44.

Trending Headlines about ACADIA Pharmaceuticals

Here are the key news stories impacting ACADIA Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised its long-term earnings outlook. The firm increased its EPS forecasts to $0.56 for FY2026, $2.95 for FY2028, $3.28 for FY2029 and $3.42 for FY2030, while maintaining a Buy rating. The revisions imply confidence in ACADIA’s earnings growth trajectory. HC Wainwright earnings estimate revisions
• Positive Sentiment: Citizens JMP raised its ACADIA price target to $36. The higher target provides additional upside relative to the recent trading level and reinforces the bullish tone surrounding the stock. Citizens JMP raises ACADIA price target
• Positive Sentiment: Recent results exceeded expectations. ACADIA reported quarterly EPS of $0.18 versus a $0.07 consensus estimate and revenue of $308 million versus expectations of $296.55 million. Revenue increased 16.4% year over year, supporting the view that operating momentum is improving. ACADIA reaches new 52-week high after earnings beat
• Positive Sentiment: Rising earnings estimates are supporting the stock. Zacks highlighted ACADIA among healthcare companies with strong earnings momentum and said recent estimate revisions could support further near-term gains. Zacks ACADIA earnings estimate outlook
• Neutral Sentiment: A separate Zacks analysis compares ACADIA’s year-to-date performance with Amneal Pharmaceuticals and the broader medical sector, providing performance context rather than a new company-specific catalyst. ACADIA performance comparison
• Negative Sentiment: HC Wainwright trimmed its Q4 2026 EPS estimate slightly to $0.20 from $0.21 and used a Hold rating in one related note, signaling some caution around near-term results. HC Wainwright quarterly estimate update

Hedge Funds Weigh In On ACADIA Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new stake in ACADIA Pharmaceuticals during the second quarter worth about $569,634,000. Norges Bank acquired a new position in shares of ACADIA Pharmaceuticals in the 4th quarter valued at approximately $40,266,000. Millennium Management LLC raised its position in shares of ACADIA Pharmaceuticals by 2,052.1% in the 3rd quarter. Millennium Management LLC now owns 1,483,235 shares of the biopharmaceutical company's stock valued at $31,652,000 after buying an additional 1,414,315 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its holdings in shares of ACADIA Pharmaceuticals by 390.1% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 1,648,864 shares of the biopharmaceutical company's stock worth $35,187,000 after acquiring an additional 1,312,426 shares during the period. Finally, First Trust Advisors LP boosted its position in shares of ACADIA Pharmaceuticals by 47.3% during the 1st quarter. First Trust Advisors LP now owns 3,343,868 shares of the biopharmaceutical company's stock worth $74,435,000 after acquiring an additional 1,073,834 shares in the last quarter. 96.71% of the stock is owned by institutional investors and hedge funds.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA's research centers concentrate on conditions with significant unmet medical needs, including Parkinson's disease psychosis, Alzheimer's disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company's flagship product, NUPLAZID® (pimavanserin), received U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source